authors
- Khalaf, Dina
- Farshchi Zarabi, Sara
- Chan, Steven
- Gupta, Vikas
- Khalaf, Dina
- Lutynski, Andrzej
- Minden, Mark D
- Rostom, Amr
- Rydlewski, Anna
- Schuh, Andre C
- Sibai, Hassan
- Yee, Karen WL
- Schimmer, Aaron D
Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- January 2, 2018
has subject area
- 1103 Clinical Sciences (FoR)
- Acute Disease (MeSH)
- Adult (MeSH)
- Aged (MeSH)
- Antineoplastic Combined Chemotherapy Protocols (MeSH)
- Cytarabine (MeSH)
- Female (MeSH)
- Humans (MeSH)
- Immunology (Science Metrix)
- Induction Chemotherapy (MeSH)
- Leukemia, Myeloid (MeSH)
- Male (MeSH)
- Middle Aged (MeSH)
- Remission Induction (MeSH)
- Survival Analysis (MeSH)
- Young Adult (MeSH)
published in
- Leukemia and Lymphoma Journal